周日报道，辉瑞和安斯泰来报告称，XTANDI加亮丙立德与单独使用亮丙立德治疗高危生化复发的非转移性激素敏感前列腺癌的死亡风险降低了40%

2025-10-20 15:41

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence1
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Final results from the Phase 3 EMBARK study are being presented in a late-breaking oral session at ESMO 2025 and simultaneouslypublished in The New England Journal of Medicine